Orion Pharma to commercialize Qilu's pembrolizumab biosimilar in Europe

Orion Pharma has signed an agreement with Qilu Pharma Europe to distribute, market, and sell an intravenous pembrolizumab biosimilar across Europe. Qilu will supply the biosimilar and receive profit share, development, regulatory, and sales milestone payments.